In chronic lymphocytic leukemia (CLL) the proliferation rate and resistance to drug-induced apoptosis are recognized as important factors in the outcome of treatment. In this study we assess the activity and the mechanism of action of the prototype Cell division cycle kinase 7 (Cdc7) inhibitor, PHA-767491, which inhibits the initiation of DNA replication but also has Cyclin dependent kinase 9 (Cdk9) inhibitory activity. We have studied the effects of this dual Cdc7/Cdk9 inhibitor in both quiescent CLL cells and CLL cells that have been induced to proliferate using a cellular co-culture system that mimics the lymph node microenvironment.
(Cdk9) inhibitory activity. We have studied the effects of this dual Cdc7/Cdk9 inhibitor in both quiescent CLL cells and CLL cells that have been induced to proliferate using a cellular co-culture system that mimics the lymph node microenvironment.
We find that this compound, originally developed as a DNA replication inhibitor, is particularly active in promoting mitochondrial dependent apoptosis in quiescent CLL cells purified from peripheral blood of patients regardless of recognized risk factors. In this setting apoptosis is preceded by a 
INTRODUCTION
Chronic Lymphocytic Leukemia (CLL) is the commonest leukemia in the western world. Despite advances in treatment, CLL remains an incurable disease. Genetic abnormalities leading to loss of TP53 function and over-expression of anti-apoptotic proteins are usually associated with short survival and represent barriers to conventional chemotherapy (1) (2) . CLL cells are predominantly found in the peripheral blood, lymphoid organs and bone marrow. CLL cells in the peripheral blood represent a population of non-dividing tumor cells which display high chemo-sensitivity; in this setting the anti-apoptotic protein Myeloid cell leukaemia sequence 1 (Mcl-1) appears to be a critical survival factor (3) (4) (5) (6) (7) . Instead CLL cells that reside in secondary lymphoid organs and the bone marrow display high chemo-resistance and proliferative capacity (8) (9) . A sub-population of CLL cells expressing the cell cycle markers Ki67 and cyclin D1 can be identified in pseudo-follicles or proliferation centres (10). In this environment the interactions between leukemic and accessory cells, such as monocyte-derived nurselike cells (NLC), CD4 + CD154 + T cells and mesenchymal stromal cells, provide essential signals to maintain CLL survival and growth (11) . Stimulated CLL cells express high levels of the anti-apoptotic members of the Bcl-2 family (12) which are likely the main determinants of increased chemo-resistance (13) . Thus, proliferation centres may harbour dividing and resistant leukemic cells, which sustain clonal maintenance, growth, and genetic diversification and may represent a relevant chemo-therapeutic target to limit tumor burden and clonal evolution.
A number of different models for pseudo-follicles have been established in vitro including culturing CLL cells on CD154 expressing fibroblasts in the presence of Interleukin-4 (IL-4) (14) . This model system partially recapitulates the phenotypic features seen in CLL cells within the proliferation centres including increased expression of the B cell lymphoma X Long (Bcl-X L ), Bcl-2 homolog A1
(Bcl-A1) and Mcl-1, acquired resistance to spontaneous-and drug-induced apoptosis and the ability to proliferate (13, 15) . Therefore, this model system may be useful in analysing the proliferative aspect of CLL and testing the efficacy of novel therapeutic agents targeting proliferation. Targeting replicating and resting CLL cells [4] The Cell cycle division 7 (Cdc7) is a protein kinase required for the initiation of DNA replication and cell cycle progression. Cdc7 phosphorylates the minichromosome maintenance 2-7 (MCM2-7) complex (16) activating its intrinsic DNA helicase activity which is the first step required to establish a competent replication fork for semi-conservative DNA synthesis. Phosphorylation of the Mcm2 subunit at Ser40 and Ser53 is observed only during S and G2/M phases of the cell cycle, mirroring Cdc7 kinase activity and is completely dependent on Cdc7 activity (17) . These phosphosites on Mcm2 have been shown to be sensitive biomarkers of Cdc7 activity in vivo.
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Cdc7 kinase is considered a promising target for cancer therapy (18) (19) . Downregulation of Cdc7 by siRNA causes apoptosis in tumor cells independently of TP53, but only arrests cell cycle progression in normal cells (20) (21) . This differential killing activity has led to the development of small molecules targeting Cdc7 kinase (18) (19) (22) (23) (24) (25) (26) . PHA-767491, the prototype of this new class of agents, has cytotoxic activity in a broad range of cancers and displays antitumor activity in various preclinical models (27) . An important feature of this compound is its cross reactivity with Cyclin dependent kinase 9 (Cdk9) and its ability to downregulate the expression of the Mcl-1 anti-apoptotic protein (27) .
In the present study, we examined the effects of the dual Cdc7/Cdk9 inhibitor PHA-767491 in both quiescent and proliferating CLL cells. Carboxyfluorescein succinimidyl ester (CFSE) was from Molecular Probes, Invitrogen (Carlsbad, CA). Fluorescein isothiocyanate (FITC, Molecular Probes)-conjugated Annexin V was prepared in house as previously described (29) . All other chemicals were from Sigma-Aldrich unless otherwise stated. Targeting replicating and resting CLL cells [6] penicillin (50 units/ml) and streptomycin (50 µg/ml). For in vitro CD40 stimulation, freshly isolated or thawed CLL cells (2 x 10 6 cell/ml) were cultured in RPMI medium on irradiated (30 Gray) NIH3T3 fibroblasts expressing human CD154 (ratio 10:1) in the presence of IL-4 (10 ng/ml). Medium and IL-4 were replaced every 3 days. Targeting replicating and resting CLL cells [7] Analysis of CLL proliferation by CFSE staining. Cells (20 x 10 6 /ml) were washed with PBS and resuspended in 1 ml of 0.1% (v/v) FBS/PBS containing 5 µM CFSE. Samples were incubated for 10 min at 37°C in the dark, then 5 volumes of cold media were added and incubated for further 5 min on ice. After 2 washes in pre-warmed media, CLL cells were plated onto NIH3T3 CD154 expressing fibroblasts in the presence of IL-4 (10 ng/ml).
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Statistical Analysis. Statistical analysis was carried out using GraphPad Prism Software (La Jolla, CA). For Figure 1 , unpaired t-test or one-way analysis of variance (ANOVA) were used to analyse the individual EC 50 versus clinical and prognostic markers. For Figure 2B , C, data were analysed using paired t-test. P values less than 0.05 were considered statistically significant. Targeting replicating and resting CLL cells [ 
Supplementary information describing cells characterization, apopotis assays, RT-qPCR and
8]
RESULTS
Peripheral blood CLL cells are sensitive to the Cdc7/Cdk9 inhibitor PHA-767491
Peripheral blood CLL cells do not proliferate (14) but surprisingly, when challenged with PHA-767491 ( Figure 1A and S1), originally developed as a DNA replication inhibitor (27) , we observed a concentration and time dependent induction of apoptosis measured by phosphatidylserine exposure (PS) ( Figure S2 ). Apoptosis was induced at 6 h and increased further at 12 h with only a marginal increase at 24 h. Based on these initial observations, we extended our studies to a cohort of 27 CLL patients with both favourable and unfavourable prognostic markers, including two patients with biallelic inactivation of TP53 (Patient #3, #11, Table S1 ) and one additional patient with known 17p deletion (Patient #23, Table S1 ). PHA-767491 induced apoptosis in all CLL samples tested with an average EC 50 of 0.6 µM at 12 h post-treatment ( Figure 1B , Table S1 ). PHA-767491 was equally 
PHA-767491 induces downregulation of Mcl-1 protein in a caspase independent manner
Since PHA-767491-induced apoptosis proceeds via Bax activation, we examined the levels of antiapoptotic Bcl-2 family members, which modulate Bax function (32) and the levels of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP), previously shown to be downregulated by PHA-767491 (27) . CLL cells were exposed to 1 µM PHA-767491 and samples were collected at different times post-treatment. Following exposure to PHA-767491, Bax and Bcl-2 protein levels remained constant in all four samples tested while Bak showed a patient specific modulation being upregulated to different degrees in three out of four samples ( Figure 2D and S4) . As Bcl-X L is poorly expressed (13) and often below the detection limit it was not analysed. However, we observed that PHA-767491 induced a rapid decrease in Mcl-1 protein levels even at 2 h in all patients tested which decreased further over time. The protein levels of XIAP also decreased, albeit to a lesser extent and with slower kinetics. Downregulation of Mcl-1 was followed by processing of pro-caspase-3, Targeting replicating and resting CLL cells [11] with CD154 expressing NIH3T3 cells (14) (15) . In this setting the kinetics of re-entry into the mitotic cell cycle, assessed both as DNA incorporation and loss of CFSE staining varied across patients starting as early as 2 days after stimulation ( Figure 4A and S5) .
Examining protein samples, and as previously reported (13, 15, 30) , we observed a rapid induction of both anti-apoptotic proteins Mcl-1 and Bcl-X L ( Figure 4B and S5) . In contrast, the levels of the Sphase kinase Cdc7 and the levels of phosphorylation of its substrate Mcm2 at Ser40, which is a considered a specific biomarker for assessing cellular Cdc7 activity (17, 27) Targeting replicating and resting CLL cells [12] Samples for protein analysis were collected after 12 h while DNA synthesis, CFSE and annexin V positivity were assessed after 24 h of treatment. We determined that 1 μM PHA-767491 had no effect while exposure to 5 μM and 10 μM PHA-767491 caused full inhibition of Cdc7 kinase activity as Proliferating CLL cells normally accumulate in the lymph nodes and to lesser extent in the bone marrow (8, 11) . Because of the relevance of the lymph node microenvironment in CLL pathobiology, we analysed the expression and the activity of Cdc7 kinase, the main molecular target of PHA-767491 in patient derived material and in an in vitro model that partially recapitulates the lymph node proliferation centres (12) (13) (14) 30) . In a preliminary analysis we report that Cdc7 is expressed and active in lymph node biopsies from CLL patients.
In vitro, following CD154 and IL-4 stimulation, we observed that CLL cells purified from peripheral blood re-express Cdc7, the key regulator of DNA synthesis. Not only is Cdc7 expressed but it is also fully functional as its key substrate, Mcm2, becomes phosphorylated thus promoting DNA replication.
In this setting, treatment with PHA-767491 was indeed proficient at blocking DNA synthesis, very likely through direct inhibition of Cdc7. In our co-culture experiments, however, we noticed that exposure to 5 or 10 µM PHA-767491 was less effective in triggering cell death than 1 µM in resting Targeting replicating and resting CLL cells [15] [21] Targeting replicating and resting CLL cells [22] Targeting replicating and resting CLL cells [23] pSer40 Mcm2 as indicated and analysed by immunofluorescence. DNA was visualised using DAPI.
Pictures were taken at 20X (I-II) and 40X (III-VI) using Olympus BX51 Upright Fluorescent Microscope with Improvision Optigrid System and Improvision Volocity Software. Arrows are 32 µm lenghts. 
